Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 2 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM033827
035-os BibID:
PMID:8875434 WOS:A1996VF15000001
Első szerző:
Kovács Magdolna
Cím:
Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats : mechanism of action / Magdolna Kovács, Gábor Halmos, Kate Groot, Jan Izdebski, Andrew V. Schally
Dátum:
1996
ISSN:
0028-3835
Megjegyzések:
To assess the efficacy of a potent agonist analog of GH-releasing hormone (GH-RH), [Dat1,Gln8,Orn12,21,Abu15,Nle27,Asp28,A gm29]hGH-RH(1-29) (JI-38), we investigated the effects of its chronic administration on growth responses in monosodium glutamate (MSG)-lesioned and normal young rats. Body weight (BW), body length (BL), tibia length (TIL), and tail length (TAL) were monitored. Basal serum GH concentrations, GH responses to bolus injections of GH-RH, pituitary GH and serum IGF-I concentrations were measured by RIA. Pituitary GH-RH receptor concentration and binding affinity was also evaluated after the treatment. Neonatal treatment with MSG resulted, as expected, in blunted growth and a decrease in serum and pituitary GH concentration and serum IGF-I levels. A reduction in GH-RH receptor concentration, associated with increased binding affinity of the GH-RH receptor was also found. Chronic administration of GH-RH agonist JI-38 in doses of 2 micrograms at 12-hour intervals for 2 weeks markedly increased the GH responsiveness to GH-RH and stimulated growth, with MSG-treated animals achieving the growth rate of normal controls. Acceleration of growth was associated with stimulated GH synthesis and IGF-I secretion, although basal serum GH levels did not change. Pituitary GH-RH receptor concentration and binding affinity were not significantly modified by the treatment. Treatment of normal young growing rats with agonist JI-38 did not further increase the normal growth acceleration in these rats, but stimulated the GH synthesis and augmented the GH secretory responsiveness. The treatment of MSG-lesioned rats with GH-RH agonist was generally more effective in female than in male animals, and in some cases masked the sex differences in growth rate. Our findings provide the first evidence that the blunted growth rate of the MSG-lesioned rats is associated with a decreased pituitary GH-RH receptor concentration. Our work demonstrates that administration of GH-RH agonist JI-38 is able to restore the normal growth rate of the GH-deficient rats by stimulating GH synthesis and IGF-I secretion.
Tárgyszavak:
Orvostudományok
Gyógyszerészeti tudományok
idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:
Neuroendocrinology. - 64 : 3 (1996), p. 169-176. -
További szerzők:
Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus)
Groot, Kate
Izdebski, Jan
Schally, Andrew Victor
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
2.
001-es BibID:
BIBFORM033611
035-os BibID:
PMID:11587553 WOS:000171671600001
Első szerző:
Schally, Andrew Victor
Cím:
Hypothalamic hormones and cancer / Andrew V. Schally, Ana Maria Comaru-Schally, Attila Nagy, Magdolna Kovacs, Karoly Szepeshazi, Artur Plonowski, Jozsef L. Varga, Gabor Halmos
Dátum:
2001
ISSN:
0091-3022
Megjegyzések:
The use of peptide analogs for the therapy of various cancers is reviewed. Inhibition of the pituitary-gonadal axis forms the basis for oncological applications of luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists, but direct effects on tumors may also play a role. Analogs of somatostatin are likewise used for treatment of various tumors. Radiolabeled somatostatin analogs have been successfully applied for the localization of tumors expressing somatostatin receptors. Studies on the role of tumoral LH-RH, growth hormone-releasing hormone (GH-RH), and bombesin/GRP and their receptors in the proliferation of various tumors are summarized, but the complete elucidation of all the mechanisms involved will require much additional work. Human tumors producing hypothalamic hormones are also discussed. Treatment of many cancers remains a major challenge, but new therapeutic modalities are being developed based on antagonists of GH-RH and bombesin, which inhibit growth factors or their receptors. Other approaches consist of the use of cytotoxic analogs of LH-RH, bombesin, and somatostatin, which can be targeted to receptors for these peptides in various cancers and their metastases. These new classes of peptide analogs should lead to a more effective treatment for various cancers.
Tárgyszavak:
Orvostudományok
Gyógyszerészeti tudományok
idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:
Frontiers In Neuroendocrinology. - 22 : 4 (2001), p. 248-291. -
További szerzők:
Comaru-Schally, Ana Maria
Nagy Attila
Kovács Magdolna
Szepesházi Károly
Plonowski, Artur
Varga József L.
Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus)
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.